跳转至内容
Merck

D1306

Sigma-Aldrich

地异喹 硫酸酯

powder, ≥98% (TLC)

别名:

3,4-二氢-2(1H)-异喹啉羧酰亚胺, Ro 5-33071, 去甲异喹 硫酸酯

登录查看公司和协议定价


About This Item

线性分子式:
C20H26N6 · H2SO4
CAS号:
分子量:
448.54
EC號碼:
MDL號碼:
分類程式碼代碼:
12352204
PubChem物質ID:
NACRES:
NA.32

product name

地异喹 硫酸酯,

化驗

≥98% (TLC)

品質等級

形狀

powder

mp

285 °C

溶解度

H2O: 20 mg/mL (with heat)

儲存溫度

room temp

SMILES 字串

OS(O)(=O)=O.NC(=N)N1CCc2ccccc2C1.NC(=N)N3CCc4ccccc4C3

InChI

1S/2C10H13N3.H2O4S/c2*11-10(12)13-6-5-8-3-1-2-4-9(8)7-13;1-5(2,3)4/h2*1-4H,5-7H2,(H3,11,12);(H2,1,2,3,4)

InChI 密鑰

CAYGYVYWRIHZCQ-UHFFFAOYSA-N

基因資訊

human ... SLC6A2(6530)

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

去异喹酮是一种抗高血压药。它可由细胞色素P4502D6所代谢。

基底

细胞色素P450 CYP2D6的底物; 细胞色素P450基因多态性的指示剂。

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

防範說明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Ping-Ching Hsu et al.
Molecular carcinogenesis, 56(2), 594-606 (2016-06-25)
Smoking-related biomarkers for lung cancer and other diseases are needed to enhance early detection strategies and to provide a science base for tobacco product regulation. An untargeted metabolomics approach by ultra-performance liquid chromatography-quadrupole-time of flight mass spectrometry (UHPLC-Q-TOF MS) totaling
E Scarr et al.
Progress in neuro-psychopharmacology & biological psychiatry, 15(2), 297-301 (1991-01-01)
1. Studies were carried out on three monoamine oxidase (MAO) inhibitors, two of which, debrisoquine and para- hydroxyphenelzine, are purported to be peripheral inhibitors and one, phenelzine, is a peripherally acting inhibitor, which has been included for comparitive purposes. 2.
B Clement et al.
Biochemical pharmacology, 46(12), 2249-2267 (1993-12-14)
The microsomal N-hydroxylation of the strongly basic guanidinium group (debrisoquine) to N-hydroxyguanidine (N-hydroxydebrisoquine) and the retroreduction of the N-hydroxyguanidine are demonstrated for the first time. The reduction of the N-hydroxyguanidine by liver homogenates and hepatocytes is catalysed by a microsomal
The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso N E, et al.
Environmental Health Perspectives, 98, 101-105 (1992)
J W Ho et al.
Analytical biochemistry, 203(2), 348-351 (1992-06-01)
Debrisoquine and sparteine are prototype substrates of a genetic deficiency in cytochrome P450-dependent drug metabolism. Sensitive assays of in vitro oxidation of sparteine and debrisoquine are required for evaluation of this polymorphism. The activities were measured by quantitative analysis of

商品

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

一期生物转化反应在药物上引入或暴露官能团,目的是增加化合物的极性。尽管一期药物代谢发生在大多数组织中,但代谢的主要和首过部位发生在肝循环期间。

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门